Loading...

Stock Performance

Data Provided by Refinitiv. Minimum 15 minutes delayed.


蚂蚁加速官网下载apk

July 31, 2024 - Apellis Pharmaceuticals Reports Second Quarter 2024 Financial Results July 7, 2024 - Apellis Completes Enrollment in Two Phase 3 Studies of the Targeted C3 Therapy, Pegcetacoplan, in Patients with Geographic Atrophy (GA) July 2, 2024 - Apellis Completes Enrollment in Phase 3 Study of Pegcetacoplan in Treatment-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

蚂蚁加速官网下载apk

蚂蚁加速官网下载apk

Investor Relations:
Argot Partners
Sam Martin / Maghan Meyers
(212) 600-1902
Email: sam@argotpartners.com / maghan@argotpartners.com

Media Relations:
Tracy Vineis
(617) 420-4839
Email: media@apellis.com

蚂蚁加速官网下载apk

Sign up to receive email alerts whenever Apellis Pharmaceuticals, Inc. posts new information to the site. Just enter your email address and click Submit.

Sign Up
加速网络连接 Email Alerts RSS Feeds Contact IR